Forest Laboratories Inc
Most Recent
Why Carl Icahn Wants a 100% Stake in Federal-Mogul Holdings
Icahn Enterprises (IEP) has been invested in auto parts maker Federal-Mogul Holdings (FDML) for almost a decade. Carl Icahn currently owns 82% of the company.
Elliott Management starts new position in Cubist Pharmaceuticals
Cubist Pharmaceuticals has grown its pipeline via acquisitions. In 2013, it acquired Trius Therapeutics, obtaining rights to tedizolid phosphate.
Millennium Management decreases position in Northeast Utilities
Northeast Utilities reported a 12% rise in profits on lower operating costs and increased investments in big power transmission projects around New England.
Millennium Management exits stake in Forest Laboratories
In July 2014, Actavis completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies.
Millennium Management adds new position in Kimberly-Clark
Kimberly-Clark Corporation (KMB) is an American personal care company that produces mostly paper-based consumer products.
Millennium Management adds new position in St. Jude Medical
St. Jude Medical, Inc. is a global medical device company founded in 1976. It has more than 20 principal operations and manufacturing facilities worldwide.
Millennium Management 3Q14 holdings
Millennium Management LLC is a privately owned and managed hedge fund founded in 1989 and headquartered in New York City.
Must-know: Icahn Associates’ 2Q14 positions
Carl Icahn is one of Wall Street’s most influential investors. He disclosed Icahn Associates Corp.’s 2Q14 positions through a 13F filing last month. The size of the U.S. long portfolio increased to $38.5 billion. It was $32.9 billion last quarter. Its only buy in the second quarter was Gannett Co. (GCI).
Overview: AQR Capital Management positions in 1Q14
AQR Capital opened new positions in the quarter—the notable ones being Riverbed Technology Inc. (RVBD) and Nordion Inc. (NDZ).
Blue Ridge Capital buys a new position in Actavis
Blue Ridge opened a new position in specialty pharmaceutical company Actavis Plc (ACT) that accounts for 2.27% of the fund’s portfolio.
Thomas Steyer’s Farallon Capital buys a new position in Actavis
Farallon Capital Management opened a new 2.29% stake in specialty pharmaceutical company Actavis PLC (ACT).
Why Tudor sold its position in Forest Laboratories?
Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]
Why did Tudor buy Intercontinental Exchange?
Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]
Why did Tudor start position in Infosys?
Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]
In high spirits? Why did Tudor open position in Beam?
Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]
